CRP and non-small cell lung carcinoma: CRP level was classified into two groups in a number of previous studies10–15, and only French study39 observed a dose-response association between CRP and mortality with a 1.8-fold higher risk of death among stage I and II but not stage III and IV NSCLC patients when comparing the highest with the lowest group of CRP (>20 mg/L vs. undetectable).